Does Dr. MUHAMMAD ABOUDAN have financial conflicts of interest?

Dr. MUHAMMAD ABOUDAN (MD) has received a total of $3,509 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $3,509 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MUHAMMAD ABOUDAN?

According to CMS Open Payments data, Dr. MUHAMMAD ABOUDAN received funding from ACTELION PHARMACEUTICALS US ($366), GLAXOSMITHKLINE ($355), and ASTRAZENECA PHARMACEUTICALS ($315).

Does Dr. MUHAMMAD ABOUDAN receive research grants or speaking fees?

Dr. MUHAMMAD ABOUDAN has received $3,509 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MUHAMMAD ABOUDAN

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: GRAND BLANC, MI 48439

NPI Number: 1457308702

LIFETIME INDUSTRY VALUE

$3,509

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABOUDAN is a verified Internal Medicine, Pulmonary Disease practitioner based in GRAND BLANC, MI.

Between 2021 and 2024, Dr. ABOUDAN had an overall industry promotional and research financial footprint of $3,509 as recorded in the federal CMS Open Payments database.

$3,509 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABOUDAN's primary funding source is ACTELION PHARMACEUTICALS US, which accounts for $366 (representing 10.4% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ACTELION PHARMACEUTICALS US

Rank 1

$366

10.4%

GLAXOSMITHKLINE

Rank 2

$355

10.1%

ASTRAZENECA PHARMACEUTICALS

Rank 3

$315

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.